治疗前[68Ga]Ga-DOTA-TATE PET与生物标志物对[177Lu]Lu-PRRT肿瘤剂量学的预测价值
该回顾性研究分析了25例接受177Lu-DOTATATE治疗的转移性神经内分泌肿瘤患者的90个病灶,评估治疗前68Ga-PET衍生指标与临床病理生物标志物对肿瘤吸收剂量的预测能力。SUVmean与吸收剂量显著相关(Spearman ρ=0.64),由SUVmean、TLSUVmean和总肝脏SUVmean构成的三变量随机森林模型预测性能最佳(R2=0.64,MAE=0.73 Gy/GBq,MRAE=0.2)。
要点
- 治疗前68Ga-PET的SUVmean与177Lu肿瘤吸收剂量显著相关(ρ=0.64)。
- 三变量随机森林模型预测肿瘤剂量最佳,R2=0.64、MAE=0.73 Gy/GBq。
- 机器学习模型优于单用SUV值或其他临床病理生物标志物。
核心结论
- 初步结果表明利用基线PET图像在177Lu-PRRT前预测吸收剂量具有可行性。
- 结合多个PET衍生指标的机器学习模型优于单用SUV值及其他所研究的临床病理生物标志物。
- 建立此类定量模型为68Ga-PET在个体化治疗计划及精准医学时代患者分层中的作用奠定基础。
研究设计与样本
- 回顾性分析25例接受177Lu-DOTATATE治疗的转移性神经内分泌肿瘤患者的90个分割病灶(男14例、女11例,年龄63.7±9.5岁,范围38-76岁)。
- 患者接受治疗前[68Ga]Ga-DOTA-TATE PET/CT及177Lu-DOTATATE输注后约4、24、96和168小时四个时间点的SPECT/CT。
- 肿瘤由放射科医师在基线CT或MRI上分割并转移至配准的PET/CT和SPECT/CT,正常器官采用基于深度学习方法在PET和SPECT的CT上分割。
- 治疗后剂量学基于SPECT/CT配准生成时间积分活度,随后采用本院蒙特卡罗吸收剂量估算方法。
- 开发多种可解释机器学习算法,采用嵌套十折交叉验证以决定系数(R2)、平均绝对误差(MAE)和平均相对绝对误差(MRAE)评估模型性能。
主要发现
- SUVmean与吸收剂量显著相关(q值<0.05,Spearman ρ=0.64),其次为TLSUVmean和SUVpeak(ρ分别为0.45和0.41)。
- 单变量分析中PET-SUVmean对治疗后吸收剂量的预测价值强于PET-SUVpeak和SUV_TNRs(R2=0.28 vs R2≤0.12)。
- 由SUVmean、TLSUVmean和总肝脏SUVmean(正常及肿瘤肝脏)构成的最优三变量随机森林模型在肿瘤剂量预测中性能最佳,R2=0.64、MAE=0.73 Gy/GBq、MRAE=0.2。
关键数值与推荐
- SUVmean与吸收剂量显著相关(q值<0.05,Spearman ρ=0.64)。
- TLSUVmean与吸收剂量的Spearman ρ=0.45,SUVpeak的Spearman ρ=0.41。
- 单变量分析中PET-SUVmean的R2=0.28,PET-SUVpeak和SUV_TNRs的R2≤0.12。
- 三变量随机森林模型预测肿瘤剂量的R2=0.64、MAE=0.73 Gy/GBq、MRAE=0.2。
临床怎么用
- 作者认为基线PET图像可用于177Lu-PRRT前预测吸收剂量。
- 作者认为结合多个PET衍生指标的机器学习模型预测性能优于单用SUV值及其他所研究的临床病理生物标志物。
- 作者认为此类定量模型为68Ga-PET在个体化治疗计划及患者分层中的应用奠定基础。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Metastatic neuroendocrine tumors (NETs) overexpressing type 2 somatostatin receptors are the target for peptide receptor radionuclide therapy (PRRT) through the theragnostic pair of 68Ga/177Lu-DOTATATE. The main purpose of this study was to develop machine learning models to predict therapeutic tumor dose using pre therapy 68Ga -PET and clinicopathological biomarkers. METHODS: We retrospectively analyzed 90 segmented metastatic NETs from 25 patients (M14/F11, age 63.7 ± 9.5, range 38-76) treated by 177Lu-DOTATATE at our institute. Patients underwent both pretherapy [68Ga]Ga-DOTA-TATE PET/CT and four timepoints SPECT/CT at ~ 4, 24, 96, and 168 h post-177Lu-DOTATATE infusion. Tumors were segmented by a radiologist on baseline CT or MRI and transferred to co-registered PET/CT and SPECT/CT, and normal organs were segmented by deep learning-based method on CT of the PET and SPECT. The SUV metrics and tumor-to-normal tissue SUV ratios (SUV_TNRs) were calculated from 68Ga -PET at the contour-level. Posttherapy dosimetry was performed based on the co-registration of SPECT/CTs to generate time-integrated-activity, followed by an in-house Monte Carlo-based absorbed dose estimation. The correlation between delivered 177Lu Tumor absorbed dose and PET-derived metrics along with baseline clinicopathological biomarkers (such as Creatinine, Chromogranin A and prior therapies) were evaluated. Multiple interpretable machine-learning algorithms were developed to predict tumor dose using these pretherapy information. Model performance on a nested tenfold cross-validation was evaluated in terms of coefficient of determination (R2), mean-absolute-error (MAE), and mean-relative-absolute-error (MRAE). RESULTS: SUVmean showed a significant correlation (q-value < 0.05) with absorbed dose (Spearman ρ = 0.64), followed by TLSUVmean (SUVmean of total-lesion-burden) and SUVpeak (ρ = 0.45 and 0.41, respectively). The predictive value of PET-SUVmean in estimation of posttherapy absorbed dose was stronger compared to PET-SUVpeak, and SUV_TNRs in terms of univariate analysis (R2 = 0.28 vs. R2 ≤ 0.12). An optimal trivariate random forest model composed of SUVmean, TLSUVmean, and total liver SUVmean (normal and tumoral liver) provided the best performance in tumor dose prediction with R2 = 0.64, MAE = 0.73 Gy/GBq, and MRAE = 0.2. CONCLUSION: Our preliminary results demonstrate the feasibility of using baseline PET images for prediction of absorbed dose prior to 177Lu-PRRT. Machine learning models combining multiple PET-based metrics performed better than using a single SUV value and using other investigated clinicopathological biomarkers. Developing such quantitative models forms the groundwork for the role of 68Ga -PET not only for the implementation of personalized treatment planning but also for patient stratification in the era of precision medicine.
引用
- Akhavanallaf A, Peterson AB, Fitzpatrick K, et al. The predictive value of pretherapy [68Ga]Ga-DOTA-TATE PET and biomarkers in [177Lu]Lu-PRRT tumor dosimetry. Eur J Nucl Med Mol Imaging. 2023. PMID: 37171633. doi:10.1007/s00259-023-06252-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。